News Sentiment

OLMA sentiment intelligence

Olema Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 11.47 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

84/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-3.7% over one week, +20.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 5.9% - Here's Why

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 84/100 classification
One-week reaction -3.7% Price reacting lower
Trend fit Trend inactive 20.6% over four weeks
Fair value -1.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 43
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 11
TradingView 9
GlobeNewswire 4
simplywall.st 3
MarketBeat 2
Simply Wall Street 2
Quartr 1

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 11
Analyst action 4
Balance sheet 2
Guidance 1
Macro sensitivity 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
MarketBeat Direct company coverage

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 5.9% - Here's Why

Olema Pharmaceuticals (NASDAQ:OLMA) saw its shares increase by 5.9% on Friday, trading at $11.7270 on lighter than usual volume. Analysts have a mixed but generally positive sentiment towards the stock, with a consensus "Moderate Buy" rating and a target price of $44.10. The comp

Tone
Positive 66/100
Event
Analyst action
Published
17 Jul 2026 17:40
Source
MarketBeat
MarketBeat Direct company coverage

Wall Street Zen Upgrades Olema Pharmaceuticals (NASDAQ:OLMA) to "Sell"

Wall Street Zen has upgraded Olema Pharmaceuticals (NASDAQ:OLMA) from "strong sell" to "sell." Despite this upgrade, the overall analyst consensus from MarketBeat remains a "Moderate Buy" with an average price target significantly higher than the current trading price. The articl

Tone
Negative 36/100
Event
Analyst action
Published
12 Jul 2026 18:09
Source
MarketBeat
TradingView Direct company coverage

Enterprise value to EBIT forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA

This article displays financial data for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) focusing on its enterprise value to EBIT forward. The content is primarily a data presentation, indicating market status as closed with no trades.

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 14:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA

This article provides financial information for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), specifically focusing on its forward price-to-earnings ratio. It seems to be a financial data snippet from TradingView, indicating no current trading activity for the stock. The article li

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 12:11
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Olema Pharmaceuticals, Inc. – BOATS:OLMA

The article displays the "Price to earnings forward" metric for Olema Pharmaceuticals, Inc. (OLMA) on the TradingView platform. It provides financial data and indicates that the market was closed with no trades. The content primarily shows navigation elements and structural infor

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 11:39
Source
TradingView
Quartr Direct company coverage

Olema Pharmaceuticals (OLMA) Jefferies London Healthcare Conference 2025 Summary

Olema Pharmaceuticals (OLMA) presented at the Jefferies London Healthcare Conference 2025, highlighting its focus on ER-positive, HER2-negative breast cancer with lead asset palazestrant currently in two pivotal Phase III trials (OPERA-01 and OPERA-02). The company also discussed

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:43
Source
Quartr
TradingView Direct company coverage

Enterprise value to EBITDA forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA

The article concerns the enterprise value to EBITDA forward metric for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA). It appears to be a financial data snippet or a preliminary page from TradingView, indicating that specific financial data for this metric would be displayed. The con

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 04:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Olema Pharmaceuticals, Inc. – BOATS:OLMA

This article provides financial information for Olema Pharmaceuticals, Inc. (OLMA), specifically focusing on its enterprise value to EBITDA forward. The data is presented within the TradingView platform, noting that the market is closed and no trades have occurred for the company

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 03:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA

This article provides a specific financial metric, "Enterprise value to revenue forward," for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA). It indicates that the value for this metric is currently unavailable or not specified, only noting the period, value, change, and percentage c

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 16:11
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA

This article provides financial information for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), focusing on its forward price to sales metric. It highlights that the data for this financial indicator is contributed by human analysis, suggesting a qualitative aspect to the valuation.

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 06:10
Source
TradingView
The Manila Times Direct company coverage

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced that it granted stock options to eight new employees to purchase 215,800 shares of common stock, effective July 1, 2026. These inducement grants were made under the Company's 2022 Inducement Plan in accordance with Nasdaq Listi

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 05:40
Source
The Manila Times
Simply Wall Street Direct company coverage

Is Olema Pharmaceuticals (OLMA) A Bargain After Its Russell Index Additions?

Olema Pharmaceuticals (OLMA) has been added to several Russell growth benchmarks, increasing its visibility to institutional investors. Despite a recent mix of share price volatility, the company's valuation, based on a discounted cash flow model, suggests it is significantly und

Tone
Positive 65/100
Event
Balance sheet
Published
03 Jul 2026 01:40
Source
Simply Wall Street
Stock Titan Direct company coverage

Olema Oncology awards 215,800 options to eight new employees

Olema Oncology (Nasdaq: OLMA) announced it granted stock options to eight new employees to purchase an aggregate of 215,800 shares of common stock, effective July 1, 2026. These inducement awards were made under its 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635

Tone
Positive 64/100
Event
Market update
Published
02 Jul 2026 20:40
Source
Stock Titan
Simply Wall Street Direct company coverage

Olema Pharmaceuticals (OLMA) Is Up 22.0% After Broad Russell Growth Index Inclusion - Has The Bull Case Changed?

Olema Pharmaceuticals (OLMA) has seen a 22% stock increase following its inclusion in multiple Russell Growth Benchmarks, including the Russell 2000, 2500, and 3000 indices. While this inclusion boosts visibility and trading liquidity, the company's investment narrative remains f

Tone
Positive 67/100
Event
Balance sheet
Published
01 Jul 2026 04:09
Source
Simply Wall Street
www.marketscreener.com Direct company coverage

Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell Small Cap Comp Growth Benchmark

Olema Pharmaceuticals, Inc. (NasdaqGS:OLMA) has been added to the Russell Small Cap Comp Growth Benchmark. This news comes amidst other recent developments for the company, including presentations at healthcare conferences and clinical trial collaborations for its experimental ca

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 17:13
Source
www.marketscreener.com
TradingView Direct company coverage

Olema Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:OLMA)

This article provides an overview of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, key financial metrics, and company information. The article also answers

Tone
Positive 61/100
Event
Analyst action
Published
26 Jun 2026 01:40
Source
TradingView
TradingView Direct company coverage

OLMA Forecast — Price Target — Prediction for 2027

Olema Pharmaceuticals, Inc. (OLMA) has a current stock price of $11.43, with analysts providing a 1-year price forecast ranging from $23.00 to $62.00, and a consensus target of $40.70. The company's stock has seen significant volatility, with a 143.71% increase over the last year

Tone
Positive 63/100
Event
Guidance
Published
25 Jun 2026 17:40
Source
TradingView
Stock Titan Direct company coverage

Olema (NASDAQ: OLMA) director receives grant of 29,500 stock options at $9.51

Olema Pharmaceuticals director Harmon Cyrus was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. The options vest in 12 equal monthly installments beginning June 18, 2026, contingent on continued service, or fully vest at the next

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 13:40
Source
Stock Titan
Stock Titan Direct company coverage

Olema (OLMA) director Graham Walmsley awarded 29,500 stock options at $9.51

Olema Pharmaceuticals director Graham G. Walmsley was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. The options will vest in 12 equal monthly installments beginning June 18, 2026, or fully on the date of Olema's next annual sto

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 13:12
Source
Stock Titan
Stock Titan Direct company coverage

Olema Pharmaceuticals (NASDAQ: OLMA) investors approve board slate, pay plan and Ernst & Young

Olema Pharmaceuticals (NASDAQ: OLMA) stockholders approved the election of four Class III directors, an advisory executive compensation program, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year at their annual

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 13:12
Source
Stock Titan
Stock Titan Direct company coverage

Olema Pharmaceuticals (OLMA) director awarded 29,500 stock options at $9.51 strike price

Olema Pharmaceuticals director Cynthia M. Butitta was granted 29,500 stock options at an exercise price of $9.51 per share. These options serve as compensation and will vest in 12 equal monthly installments starting June 18, 2026, provided she continues her service. Any unvested

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 13:12
Source
Stock Titan
Stock Titan Direct company coverage

Olema (OLMA) director receives 29,500 options at $9.51 strike price

Olema Pharmaceuticals director Sandra Horning was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. The options will vest in 12 equal monthly installments starting June 18, 2026, contingent on her continuous service, with any unves

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 01:09
Source
Stock Titan
Stock Titan Direct company coverage

Olema (OLMA) director Garland J. Scott awarded 29,500 stock options at $9.51

Olema Pharmaceuticals director Garland J. Scott was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. These options vest in 12 equal monthly installments starting June 18, 2026, contingent on Scott's continuous service. This grant

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 01:09
Source
Stock Titan
Stock Titan Direct company coverage

Olema (NASDAQ: OLMA) director granted 29,500 stock options at $9.51 strike price

Olema Pharmaceuticals director Andrew Rappaport was granted 29,500 stock options at an exercise price of $9.51 per share, as part of his compensation. These options, which expire on June 18, 2036, vest in 12 equal monthly installments starting June 18, 2026, or fully on the next

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 01:09
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Olema Pharmaceuticals Inc For: 23 June By Investing.com

This article announces the filing of Form 4 for Olema Pharmaceuticals Inc. on June 23. It notes that the company's stock, OLMA, showed a 5.79% increase and includes various financial market data and related news. The content is primarily a brief announcement paired with general m

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 22:32
Source
Investing.com Nigeria